Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06007911 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT06007911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06007911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Withdrawn
Start date
August 31, 2024
Completion date
April 30, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory aml, relapsed adult aml